Anti-Infective Market: By Product Type (Antibacterials, Antifungals), By Indication (Pneumonia, Methicillin-resistant Staphylococcus Aureus (MRSA), Sepsis, Tuberculosis, Dermatophytosis, Aspergillosis, Candidiasis, Hepatitis Virus Infection, HIV Infection, Respiratory Virus Infection Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Specialty Pharmacy, E-commerce Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

1. Executive Summary
2. Global Anti-Infective Market Introduction
2.1. Global Anti-Infective Market - Taxonomy
2.2. Global Anti-Infective Market -Definitions
2.2.1. By Product Type
2.2.2. By Indication
2.2.3. By Distribution Channel
2.2.4. By Region
3. Global Anti-Infective Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anti-Infective Market Dynamic Factors - Impact Analysis
3.6. Global Anti-Infective Market - Competition Landscape
4. Global Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Anti-Infective Market, By Product Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.1. Antibacterials
5.1.1. Cephalosporins
5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Penicillin
5.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Fluoroquinolones
5.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Macrolides
5.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Carbapenems
5.1.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.1.6. Others
5.1.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.6.3. Market Opportunity Analysis
5.2. Antifungals
5.2.1. Azoles
5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Echinocandins
5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Polyenes
5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Others
5.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.3. Antivirals
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Anti-Infective Market Forecast, By Indication, 2018-2022 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.1. Pneumonia
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Sepsis
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Tuberculosis
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Dermatophytosis
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Aspergillosis
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Candidiasis
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Hepatitis Virus Infection
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. HIV Infection
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Respiratory Virus Infection
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Others
6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
6.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
7. Global Anti-Infective Market, By Distribution Channel, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Specialty Pharmacy
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. E-commerce
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Others
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8. Global Anti-Infective Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Anti-Infective Market - Opportunity Analysis Index, By Product Type, Indication, Distribution Channel, and Region, 2023-2029
9. North America Anti-Infective MarketAnalysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
9.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Antibacterials
9.1.1.1. Cephalosporins
9.1.1.2. Penicillin
9.1.1.3. Fluoroquinolones
9.1.1.4. Macrolides
9.1.1.5. Carbapenems
9.1.1.6. Others
9.1.2. Antifungals
9.1.2.1. Azoles
9.1.2.2. Echinocandins
9.1.2.3. Polyenes
9.1.2.4. Others
9.1.3. Antivirals
9.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Pneumonia
9.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
9.2.3. Sepsis
9.2.4. Tuberculosis
9.2.5. Dermatophytosis
9.2.6. Aspergillosis
9.2.7. Candidiasis
9.2.8. Hepatitis Virus Infection
9.2.9. HIV Infection
9.2.10. Respiratory Virus Infection
9.2.11. Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Specialty Pharmacy
9.3.4. E-commerce
9.3.5. Others
9.4. Country Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Anti-Infective Market - Opportunity Analysis Index, By  Product Type, Indication, Distribution Channel, and Country, 2023-2029
9.6. North America Anti-Infective Market Dynamics - Trends
10. Europe Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
10.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antibacterials
10.1.1.1. Cephalosporins
10.1.1.2. Penicillin
10.1.1.3. Fluoroquinolones
10.1.1.4. Macrolides
10.1.1.5. Carbapenems
10.1.1.6. Others
10.1.2. Antifungals
10.1.2.1. Azoles
10.1.2.2. Echinocandins
10.1.2.3. Polyenes
10.1.2.4. Others
10.1.3. Antivirals
10.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Pneumonia
10.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
10.2.3. Sepsis
10.2.4. Tuberculosis
10.2.5. Dermatophytosis
10.2.6. Aspergillosis
10.2.7. Candidiasis
10.2.8. Hepatitis Virus Infection
10.2.9. HIV Infection
10.2.10. Respiratory Virus Infection
10.2.11. Others
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Specialty Pharmacy
10.3.4. E-commerce
10.3.5. Others
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Anti-Infective Market - Opportunity Analysis Index, By  Product Type, Indication, Distribution Channel, and Country, 2023-2029
10.6. Europe Anti-Infective Market Dynamics - Trends
11. Asia-Pacific Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
11.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antibacterials
11.1.1.1. Cephalosporins
11.1.1.2. Penicillin
11.1.1.3. Fluoroquinolones
11.1.1.4. Macrolides
11.1.1.5. Carbapenems
11.1.1.6. Others
11.1.2. Antifungals
11.1.2.1. Azoles
11.1.2.2. Echinocandins
11.1.2.3. Polyenes
11.1.2.4. Others
11.1.3. Antivirals
11.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Pneumonia
11.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
11.2.3. Sepsis
11.2.4. Tuberculosis
11.2.5. Dermatophytosis
11.2.6. Aspergillosis
11.2.7. Candidiasis
11.2.8. Hepatitis Virus Infection
11.2.9. HIV Infection
11.2.10. Respiratory Virus Infection
11.2.11. Others
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Specialty Pharmacy
11.3.4. E-commerce
11.3.5. Others
11.4. Country Analysis2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Anti-Infective Market - Opportunity Analysis Index, By  Product Type, Indication, Distribution Channel, and Country, 2023-2029
11.6. Asia-Pacific Anti-Infective Market Dynamics - Trends
12. Latin America Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
12.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antibacterials
12.1.1.1. Cephalosporins
12.1.1.2. Penicillin
12.1.1.3. Fluoroquinolones
12.1.1.4. Macrolides
12.1.1.5. Carbapenems
12.1.1.6. Others
12.1.2. Antifungals
12.1.2.1. Azoles
12.1.2.2. Echinocandins
12.1.2.3. Polyenes
12.1.2.4. Others
12.1.3. Antivirals
12.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Pneumonia
12.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
12.2.3. Sepsis
12.2.4. Tuberculosis
12.2.5. Dermatophytosis
12.2.6. Aspergillosis
12.2.7. Candidiasis
12.2.8. Hepatitis Virus Infection
12.2.9. HIV Infection
12.2.10. Respiratory Virus Infection
12.2.11. Others
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Specialty Pharmacy
12.3.4. E-commerce
12.3.5. Others
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Anti-Infective Market - Opportunity Analysis Index, By  Product Type, Indication, Distribution Channel, and Country, 2023-2029
12.6. Latin America Anti-Infective Market Dynamics - Trends
13. Middle East and Africa Anti-Infective Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
13.1. By Product Type Analysis 2018-2022 and Forecast 2023-2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antibacterials
13.1.1.1. Cephalosporins
13.1.1.2. Penicillin
13.1.1.3. Fluoroquinolones
13.1.1.4. Macrolides
13.1.1.5. Carbapenems
13.1.1.6. Others
13.1.2. Antifungals
13.1.2.1. Azoles
13.1.2.2. Echinocandins
13.1.2.3. Polyenes
13.1.2.4. Others
13.1.3. Antivirals
13.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Pneumonia
13.2.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
13.2.3. Sepsis
13.2.4. Tuberculosis
13.2.5. Dermatophytosis
13.2.6. Aspergillosis
13.2.7. Candidiasis
13.2.8. Hepatitis Virus Infection
13.2.9. HIV Infection
13.2.10. Respiratory Virus Infection
13.2.11. Others
13.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Specialty Pharmacy
13.3.4. E-commerce
13.3.5. Others
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Anti-Infective Market - Opportunity Analysis Index, By  Product Type, Indication, Distribution Channel, and Country, 2023-2029
13.6. MEA Anti-Infective Market Dynamics - Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Gilead Sciences
14.2.2. GlaxoSmithKline
14.2.3. Merck & Co
14.2.4. Johnson & Johnson
14.2.5. Pfizer Inc.
14.2.6. AbbVie
14.2.7. Bayer AG
14.2.8. Mylan N.V.
14.2.9. Shionogi
14.2.10. F. Hoffmann-La Roche Ltd
15. Research Methodology
16. Key Assumptions and Acronyms

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

The anti-infective market key players are: Gilead Sciences, GlaxoSmithKline, Merck & Co, Johnson & Johnson, Pfizer Inc., AbbVie, Bayer AG, Mylan N.V., Shionogi, Hoffmann-La Roche Ltd

  • Gilead Sciences
  • GlaxoSmithKline
  • Merck & Co
  • Johnson & Johnson
  • Pfizer Inc.
  • AbbVie
  • Bayer AG
  • Mylan N.V.
  • Shionogi
  • Hoffmann-La Roche Ltd

Adjacent Markets

Western Europe Capsule Endoscopy Market
Viral Hepatitis Market
Specialty Generics Market
Respiratory Syncytial Virus (RSV) Therapeutics Market
Relapsed or Refractory B Cell Malignancies Market
Rare Diseases Therapeutics Market